JNJ’s debt‑to‑equity ratio remains conservative, a factor integrated into bullish forecast models that anticipate ongoing capacity for acquisitions and product development. Investors are also bullish on the company. According to Insider Monkey’s database for Q4 2024, 98 hedge funds held a stake in Johnson & Johnson (NYSE:JNJ), up from 81 at the end of the third quarter. Mar Vista U.S. Quality Select Strategy stated the following regarding JNJ in its Q1 2025 investor letter : To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. Macro forecasts for the healthcare industry remain strong, with aging population trends benefiting JNJ’s long‑term earnings. This underpins a steady JNJ stock forecast despite broader market uncertainty.